Effect of metformin and rosiglitazone in non-obese polycystic ovary syndrome women with insulin resistance
10.3760/cma.j.cn112141-20210424-00224
- VernacularTitle:两种胰岛素增敏剂二甲双胍与罗格列酮治疗胰岛素抵抗的非肥胖PCOS患者效果比较
- Author:
Jing TAN
1
;
Guojun ZHOU
;
Qiuyi WANG
;
Tingting LIU
;
Qi CAO
;
Wei HUANG
Author Information
1. 四川大学华西第二医院生殖医学科 出生缺陷与相关妇儿疾病教育部重点实验室，成都 610041
- Keywords:
Polycystic ovary syndrome;
Insulin resistance;
Metformin;
Rosiglitazone Clinical trial registration: Chinese Clinical Trial Registry, ChiCTR-TRC-130
- From:
Chinese Journal of Obstetrics and Gynecology
2021;56(7):467-473
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate effects of metformin and rosiglitazone in non-obese polycystic ovary syndrome (PCOS) women with insulin resistance.Methods:Totally 200 non-obese PCOS women with insulin resistance in West China Second Hospital of Sichuan University were enrolled into this study from Sep. 2013 to Jun. 2016, and were randomly divided into two treatment groups: metformin group (1 500 mg/d) and rosiglitazone group (4 mg/d). The treatment lasted for 6 months. Their clinical and biochemical parameters were collected and compared.Results:In both groups, menstrual cycles [metformin group (37±4) days, rosiglitazone group (35±4) days] were shorter after treatment for 6 months (both P<0.01). After treatment for 6 months, body mass index [metformin group (21.6±1.6) kg/m 2, rosiglitazone group (21.7±1.7) kg/m 2] decreased in both groups (both P<0.01); decreased LH/FSH ratio (metformin group 1.67±0.80, rosiglitazone group 1.70±0.83) was also observed (both P<0.05). After treatment for 6 months, fasting insulin level [metformin group (13.5±5.1) mU/L, rosiglitazone group (12.7±5.6) mU/L] and homeostasis model assessment-insulin resistance index (metformin group 3.0±1.2, rosiglitazone group 2.8±1.2) were decreased in both groups (all P<0.01). Conclusions:For non-obese PCOS insulin resistance patients, screening of anthropometric and metabolic parameters is necessary. For PCOS with insulin resistance, lifestyle plus insulin sensitizers such as metformin could improve their clinical symptoms, correct the biochemical and metabolic dysfunction.
